ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
- The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
- A second cohort of IOS-1002 in combination with pembrolizumab will be initiated after completion of the fifth dose level.
- The Phase 1a/b trial is expected to enroll over 120 patients.
- "We are pleased that the trial is progressing as planned," said Christoph Renner, M.D., CMO and co-founder of ImmunOs Therapeutics.